References:
- Gupta A, Thompson D, Whitehouse A, et al. 2017. Adverse events
associated with unblinded, but not with blinded, statin therapy in the
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm
(ASCOT-LLA): a randomised double-blind placebo-controlled trial and
its non-randomised non-blind extension phase. Lancet
2017;389:2473-2481.
- Mammen, Andrew L. 2016. Statin-Associated Autoimmune Myopathy N Engl J
Med 2016; 374:664-669
- Nazir S, Lohani S, Tachamo N, Poudel D, Donato A. 2017.
Statin-Associated Autoimmune Myopathy: A Systematic Review of 100
Cases. J Clin Rheumatol. 2017 Apr;23(3):149-154.
- Gu HM, Zhang DW. 2015. Hypercholesterolemia, low density lipoprotein
receptor and proprotein convertase subtilisin/kexin-type 9. J
Biomed Res . 2015;29(5):356-361. doi:10.7555/JBR.29.20150067
- Oesterle A, Liao JK. 2019. The Pleiotropic Effects of Statins - From
Coronary Artery Disease and Stroke to Atrial Fibrillation and
Ventricular Tachyarrhythmia. Curr Vasc Pharmacol .
2019;17(3):222-232. doi:10.2174/1570161116666180817155058
- Lucile Musset, Yves Allenbach, Olivier Benveniste, Olivier Boyer,
Xavier Bossuyt, et al. 2016. Anti-HMGCR antibodies as a biomarker for
immune-mediated necrotizing myopathies: A history of statins and
experience from a large international multi-center study. Autoimmunity
Reviews 15 (2016) 983–993